



EMMESSAR BIOTECH & NUTRITION LIMITED

29, Kamer Building, 4th floor, 38, Cawasji Patel Street, Fort, Mumbai – 400 001
Tel: 022-35661373 / 35664530 Email: enquiries@ebnl.org Website: www.ebnl.org
Investors Grievance Email: investors@ebnl.org CIN No. L24110MH1992PLC065942

Date: August 14, 2024

To,
The Manager
Listing Department,
Bombay Stock Exchange Limited,
P. J. Tower, Dalal Street,
Mumbai – 400 001

Ref: -Security Code No.524768
Sub: Outcome of Board Meeting

The Board of Directors at their meeting held today i.e. August 14, 2024 has transacted the following items of business:

1. Unaudited Financial Results for the Quarter ended June 30, 2024:

Pursuant to Regulation 33(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are forwarding herewith a copy of Unaudited Financial Results for the Quarter ended 30.06.2024.

The above results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 14.08.2024 (i.e. today).

We also enclose "Limited Review Report" dated 14.08.2024, issued by Statutory Auditors, M/s. V. Nagarajan & Co., Chartered Accountant(s), FRN No.: 004879N, in respect of Unaudited Financial Results for the Quarter ended 30.06.2024. The results are attached at "Annexure A".

2. Annual General Meeting:

The 32nd Annual General Meeting of the Company is scheduled to be held on Friday September 27, 2024 at 11:30 a.m. through video conferencing pursuant to General Circular Nos. 14/2020, 17/2020, 20/2020, 02/2021, 21/2021, 02/2022, 10/2022 and 09/2023 dated April 8, 2020, April 13, 2020, May 5, 2020, January 13, 2021, December 14, 2021, May 5, 2022, December 28, 2022 and September 25, 2023, respectively ("MCA Circulars") (hereinafter collectively referred to as "MCA Circulars") and Circular No. SEBI/HO/CFD/CMD1/CIR/P/2020/79 dated May 12, 2020, Circular No. SEBI/HO/CFD/CMD2/CIR/P/2022/62 dated May 13, 2022, Circular No. SEBI/HO/CFD/PoD-2/P/CIR/2023/4 dated January 5, 2023 and Circular No. SEBI/HO/CFD/CFD-PoD-2/P/CIR/2023/167 dated October 7, 2023 ("SEBI circulars") has provided certain relaxations from compliance with certain provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), issued in this behalf.

In compliance with these MCA and SEBI Circulars, provisions of the Companies Act, 2013 (the "Act") and the Listing Regulations, the ensuing 32nd AGM of the Company will be conducted through VC/ OAVM facility, which does not require physical presence of members at a common venue. The deemed venue for the 32nd AGM shall be the Registered Office of the Company.

Regd. Office & Factory: Plot No. T-3/2, MIDC Area, Taloja – 410208. Dist. Raigad. Maharashtra.
Email: enquiries@ebnl.org Website: www.ebnl.org



EMMESSAR BIOTECH & NUTRITION LIMITED

29, Kamer Building, 4th floor, 38, Cawasji Patel Street, Fort, Mumbai – 400 001

Tel: 022-35661373 / 35664530 Email: enquiries@ebnl.org Website: www.ebnl.org

Investors Grievance Email: investors@ebnl.org CIN No. L24110MH1992PLC065942

3. **E voting and Cut-off date:**

In compliance with the provisions of Section 108 of the Companies Act, 2013, read with Rule 20 Companies (Management and Administration) Rules as amended up to date and Regulation 44 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, the Company has decided to provide the facility to members to exercise their right to vote at the Annual General Meeting (AGM) by electronic means and the business may be transacted through e-Voting services provided by Link Intime India Pvt. Ltd (LI IPL).

The cutoff date for the limited purpose of remote e-voting is September 20, 2024.

The remote e-voting period will commence on Tuesday, September 24, 2024 at 09:00 A.M. IST and end on Thursday, September 26, 2024 at 5:00 P.M IST. During this period shareholders of the Company, holding shares either in physical form or in dematerialised form, as on cut-off date i.e. Friday, September 20, 2024, may cast their vote electronically.

The Meeting commenced at 12:00 noon and concluded at 1:20 p.m.

Kindly take the above on record.

For **EMMESSAR BIOTECH & NUTRITION LIMITED**

M S Raghavan Ayyangar
(Managing Director)

Encl: As above



V NAGARAJAN & CO.

Chartered Accountants

Limited Review Report on Unaudited Financial Results of Emmessar Biotech & Nutrition Limited for the Quarter ended 30th June 2024 pursuant to Regulation 33 of Securities and Exchange Board of India(Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Emmessar Biotech & Nutrition Limited

1. We have reviewed the accompanying Statement of unaudited financial results of **Emmessar Biotech & Nutrition Limited** ("the Company") for the quarter ended 30th June 2024, ("The Statement").
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of Securities and Exchange Board of India(Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Our responsibility is to issue a report on the statement based on our review.
3. We conducted our review in accordance with the Standards on Review Engagements (SRE) 2410, 'Review on Interim Financial Information Performed by the Independent auditor of the Entity' issued by the Institute of Chartered Accountants of India. These standards require that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to enquiries of the Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**Place: Hyderabad
Date: 14th August, 2024**

**For V Nagarajan & Co.
Chartered Accountants
ICAI Firm Regn. No. 004879N**

CHERUKU Digitally signed by
PALLY CHERUKUPALLY
SHANKAR
Date: 2024.08.14
SHANKAR 13:18:47 +05'30'

**Shankar Cherekupally
Partner
Membership No. 252304
UDIN: 24252304BKFSCM7724**

EMMESSAR BIOTECH & NUTRITION LIMITED
 Regd Office: T-3/2, MIDC, Taloja, Raigad District, Maharashtra State
 CIN: L24110MH1992PLC06594229

UNAUDITED FINANCIAL RESULTS (STANDLONE) FOR THE QUARTER ENDED 30TH JUNE 2024

Sr. No	Particulars	(Rupees in Lakhs)			
		Quarter Ended		Year Ended	
		30.06.2024 Unaudited	31.03.2024 Audited	30.06.2023 Unaudited	31.03.2024 Audited
PART A					
1	Revenue from Operations	7.92	7.53	6.77	55.52
2	Other Income	45.73	48.36	45.71	199.21
	Total Income (1 + 2)	53.65	55.89	52.48	254.73
PART B					
3	Expenses				
	Cost of material consumed	1.04	2.48	1.62	6.34
	Purchase of Stock-trade	0.00	0.00	0.00	10.88
	Change in Inventories of Finished goods	1.23	-0.53	-0.03	2.60
	Employee Benefit Expenses	23.29	24.52	22.26	95.68
	Depreciation & Amortisation of Assets	2.44	2.44	2.44	9.76
	Other Expenditure	9.83	20.32	10.25	48.20
	Total Expenses	37.82	49.22	36.54	173.47
4	Profit / (loss) from Operations before exceptional items & Tax (A-B)	15.84	6.67	15.94	81.26
5	Exceptional items	0.00	0.00	0.00	0
6	Profit / (loss) before tax (4 - 5)	15.84	6.67	15.94	81.26
7	Tax Expenses				
	1. Current Tax	-3.00	-3.21	-4.50	-24.76
	2. Deferred Tax	-3.94	13.06	-5.95	-1.87
	3. MAT Credit available	0.00	0.00	0.00	0.00
	4. Excess/short provision of earlier years	0.00	20.33	0.00	20.33
8	Net Profit / (loss) after tax (6 - 7)	8.90	36.85	5.49	74.96
9	Other Comprehensive Income	0.00	-1.17	0.00	-1.17
10	Total comprehensive income and Other Comprehensive Income	8.90	35.68	5.49	73.79
11	Paid-up Equity Share Capital	499.61	499.61	499.61	499.61
	(Face Value of the share)	10.00	10.00	10.00	10.00
	Earning per Shares				
	1. Basic	0.18	0.71	0.11	1.48
	2. Diluted	0.18	0.71	0.11	1.48

Notes:

- The above results were taken on record by the Board of Directors and the Audit Committee at their meeting held on 14th August 2024 and have been subjected to Limited Review by the Statutory Auditors. The review report of the Statutory Auditors is being filed with the BSE.
- Financial results for all the periods presented have been prepared in accordance with the Companies (Indian Accounting Standards (Rules), 2015 (as amended from time to time) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- The Company operates two segments ie. Healthcare and rent on leasehold land during this quarter.
- No Investor Compliant was received for the quarter ended 30th June 2024


 Srinivasa Raghavan Mathurakavi Ayyangar
 Chairman & Managing Director
 DIN: 00090266

Mumbai
 14-Aug-24

EMMESSAR BIOTECH & NUTRITION LIMITED						
Regd Office: T-3/2, MIDC, Taloja, Raigad District, Maharashtra State						
CIN: L24110MH1992PLC06594229						
Segmentwise Revenue, Results and Capital Employed for the Quarter Ended 30th June 2024						
[Rs. In Lakhs]						
		Quarter Ended			Year Ended	
		30.06.2024 Unaudited	31.03.2024 Audited	30.06.2023 Unaudited	31.03.2024 Audited	
1	1. Segment Revenue					
a	Healthcare	7.92	7.53	6.77	55.52	
b	Rent on Leasehold Land	37.16	37.16	37.16	148.64	
c	Others	8.57	11.19	8.55	50.57	
	Total:	53.65	55.88	52.48	254.73	
	Less: Inter Segment Revenue	-	-	-	-	
	Net Sales / Income from Operations	53.65	55.88	52.48	254.73	
2	2 Segment Results (Profit / Loss) tax					
a	Healthcare	5.15	4.47	4.29	32.44	
b	Rent on Leasehold Land	36.93	36.93	36.93	148.64	
c	Others	8.57	11.19	8.55	50.57	
	Total:	50.65	52.60	49.77	231.65	
	Less:					
	Interest	-	-	-	-	
	Other Unallocable Expenditure (Net off)	34.81	45.93	33.83	150.39	
	Total Profit before Tax & Exceptional items	15.84	6.67	15.94	81.26	
3	3 Capital Employed (Segment Assets - Segment Liabilities)					
a	Healthcare	12.01	10.24	12.60	10.24	
b	Leasehold Land	-1.89	-1.66	-0.95	-1.66	
c	Others	728.34	714.73	653.97	714.73	
	Total:	738.46	723.30	665.62	723.30	
<p>Note: The Fixed Assets are employed for the general enterprise and are not segmental in nature.</p> <p>The above results were taken on record at a meeting of the Board of Directors held on 14th August 2024</p> <p>Mumbai 14-Aug-24</p> <p style="text-align: right;">By order of the Board Srinivasa Raghavan Mathurakavi Ayyangar Chairman & Managing Director DIN: 00090266</p>						